炎症性肠病生物制剂处方与制药行业向医生支付款项之间的关联。
Association of Biologic Prescribing for Inflammatory Bowel Disease With Industry Payments to Physicians.
作者信息
Khan Rishad, Nugent Cameron M, Scaffidi Michael A, Gimpaya Nikko, Grover Samir C
机构信息
Division of Gastroenterology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Department of Integrative Biology, University of Guelph, Guelph Ontario, Canada.
出版信息
JAMA Intern Med. 2019 Oct 1;179(10):1424-1425. doi: 10.1001/jamainternmed.2019.0999.
Abstract
This economic evaluation examines whether pharmaceutical industry payments to gastroenterologists are associated with how often they prescribe the pharmaceuticals’ drugs for inflammatory bowel disease.
摘要
这项经济评估考察了制药行业向胃肠病学家支付的费用是否与他们为炎症性肠病开该制药公司药物的频率有关。
相似文献
1
Association of Biologic Prescribing for Inflammatory Bowel Disease With Industry Payments to Physicians.
JAMA Intern Med. 2019 Oct 1;179(10):1424-1425. doi: 10.1001/jamainternmed.2019.0999.
2
Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
JAMA Intern Med. 2016 Jun 1;176(6):763-8. doi: 10.1001/jamainternmed.2016.1709.
3
Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
BMC Health Serv Res. 2018 Apr 2;18(1):236. doi: 10.1186/s12913-018-3043-8.
4
Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):819-826. doi: 10.1002/pds.4224. Epub 2017 May 9.
5
Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
JAMA Intern Med. 2016 Aug 1;176(8):1114-1122. doi: 10.1001/jamainternmed.2016.2765.
6
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
BMJ. 2016 Aug 18;354:i4189. doi: 10.1136/bmj.i4189.
7
Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs.
PLoS One. 2016 May 16;11(5):e0155474. doi: 10.1371/journal.pone.0155474. eCollection 2016.
8
The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids.
Otolaryngol Head Neck Surg. 2018 Sep;159(3):442-448. doi: 10.1177/0194599818774739. Epub 2018 Jun 5.
9
Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors.
Otolaryngol Head Neck Surg. 2019 Jan;160(1):70-76. doi: 10.1177/0194599818803337. Epub 2018 Oct 16.
10
Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
JAMA Ophthalmol. 2016 Aug 1;134(8):897-903. doi: 10.1001/jamaophthalmol.2016.1678.
引用本文的文献
1
Unsolicited Patient Complaints and Industry Payments for US Physicians.
JAMA Netw Open. 2025 Aug 1;8(8):e2526643. doi: 10.1001/jamanetworkopen.2025.26643.
2
Non-research payments to board-certified cardiologists from pharmaceutical industry in Japan from 2016 to 2019: a retrospective analysis.
BMJ Open. 2024 Jul 31;14(7):e083445. doi: 10.1136/bmjopen-2023-083445.
3
Comparison of industry payments to psychiatrists and psychiatric advanced practice clinicians in the USA, 2021: a cross-sectional study.
BMJ Open. 2024 Feb 8;14(2):e081252. doi: 10.1136/bmjopen-2023-081252.
4
Characteristics of Advanced Practice Nurses Receiving Top Industry Payments and Their Practice Settings: a Cross-sectional Study.
J Gen Intern Med. 2024 May;39(7):1142-1148. doi: 10.1007/s11606-023-08508-6. Epub 2023 Nov 14.
5
Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019.
Cureus. 2023 Aug 17;15(8):e43633. doi: 10.7759/cureus.43633. eCollection 2023 Aug.
6
Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019.
Sci Rep. 2023 May 8;13(1):7425. doi: 10.1038/s41598-023-34705-8.
7
Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019.
BMJ Open. 2023 Apr 18;13(4):e068237. doi: 10.1136/bmjopen-2022-068237.
8
Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease.
J Can Assoc Gastroenterol. 2022 Jun 1;5(5):214-220. doi: 10.1093/jcag/gwac018. eCollection 2022 Oct.
9
Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020.
Clin Microbiol Infect. 2022 Dec;28(12):1655.e1-1655.e4. doi: 10.1016/j.cmi.2022.07.023. Epub 2022 Aug 5.
10
Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?
J Health Polit Policy Law. 2022 Dec 1;47(6):815-833. doi: 10.1215/03616878-10041205.
Zotero 插件